ClinicalTrials.gg
TerminatedNCT05714345EXPANDUpdated Mar 2, 2026Results posted

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

A Phase 2 interventional study of ALLO-647 and Fludarabine in Relapsed/Refractory Large B Cell Lymphoma, sponsored by Allogene Therapeutics. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Primary conditionLymphomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Allogene Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated early for business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies testing fludarabine in Lymphoma — 8 open to participants now, 13 under way, none of them phase 3. fludarabine · Lymphoma.

Enrollment
92nd of 103
2 · median 31
Started
2023
with 2 others
Phase 2
55 of 106
2 open now
Registered
99th of 106
by date

Among the 106 studies testing fludarabine in Lymphoma, this one is the 92nd largest by enrollment of the 103 interventional ones that give a count, is one of 3 that started in 2023, is one of 55 in phase 2, and was the 99th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

8 of the 106 studies testing fludarabine in Lymphoma are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing fludarabine in Lymphoma, or all of them as a file.
02

Study summary

The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma

03

Conditions studied

  • Relapsed/Refractory Large B Cell Lymphoma

Browse trials for

Keywords

  • CAR T
  • Cell Therapy
  • Allogeneic Cell Therapy
  • Cellular Immuno-therapy
  • AlloCAR T
  • ALLO-501A
  • ALLO-647
  • LBCL
  • Lymphoma
  • Large B-Cell Lymphoma
04

In context

Lymphoma Reclassified

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

This study's enrollment of 2 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Allogene Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Compared within Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of large B-cell lymphoma at last relapse
  • Relapsed or refractory disease after at least 2
  • performance status 0 or 1
  • Absence of significant donor (product)-specific anti-HLA antibodies (DSA)
  • Adequate hematological, renal and liver function

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system involvement by
  • or allogeneic HSCT within last 6 months prior to lymphodepletion
  • Hypocellular bone marrow for age
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Lymphodepletion with ALLO-647, fludarabine, and cyclophosphamide

    ALLO-501A CAR T cells infused following lymphodepletion

    Biological: ALLO-647 · Drug: Fludarabine · Drug: Cyclophosphamide · Genetic: ALLO-501A

  • Experimental
    Lymphodepletion with fludarabine and cyclophosphamide

    ALLO-501A CAR T cells infused following lymphodepletion

    Drug: Fludarabine · Drug: Cyclophosphamide · Genetic: ALLO-501A

Interventions

  • BiologicalALLO-647

    ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

  • Chemotherapy for lymphodepletion

  • Chemotherapy for lymphodepletion

  • GeneticALLO-501A

    ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

07

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review Committee

    To assess the clinical efficacy of ALLO-647 (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by PFS and assessed by Independent Review Committee (IRC) in subjects with R/R (Relapsed / Refractory) LBCL (Large B Cell Lymphoma). In this study, PFS is defined as the time from randomization to disease progression, or relapse per the Lugano classification criteria (Cheson et al, 2014) as assessed by IRC or death.

    Time frame: Up to 60 months

Secondary outcomes

  1. Overall-response Rate (ORR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee

    To assess the clinical efficacy of ALLO-647 as measured by ORR and assessed by Independent Review Committee (IRC) between treatment arms. ORR is defined as best overall response (Complete Response and Partial Response, assessed using the Lugano classification criteria 2014; Cheson , et al, 2014) by IRC at any time up through commencement of new anti-cancer therapy or withdrawal of consent.

    Time frame: Up to 60 months

  2. Event-Free-Survival (EFS) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee

    To assess clinical efficacy of ALLO-647 with FC (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by Event-Free Survival (EFS) and assessed by Independent Review Committee (IRC) in subjects with R/R LBCL. EFS is defined as the time from randomization to disease progression or relapse per the Lugano classification criteria 2014 as assessed by IRC, new anti-cancer therapy, or death.

    Time frame: Up to 60 months

  3. Duration of Response (DOR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee

    To characterize the efficacy of ALLO-647 as measured by Duration of Response (DOR) and assessed by Independent Review Committee (IRC) between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse (per IRC) or death.

    Time frame: Up to 60 months

  4. Overall Survival (OS) of a Lymphodepletion Regimen Containing FCA vs FC

    To characterize the efficacy of ALLO-647 as measured by OS, defined as the time from randomization to death.

    Time frame: Up to 60 months, study completion, or death, whichever occurs earlier. Specifically, OS was followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.

  5. Duration of Response, Event-Free Survival and Progression-Free Survival of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review

    To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Duration of Response (DOR), Event-Free Survival (EFS), Progression-Free Survival (PFS), assessed by investigator assessments between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse per investigator assessment, or death. EFS is defined as the time from randomization to disease progression or relapse per investigator assessment per the Lugano classification criteria, new anti-cancer therapy, or death. PFS is defined as time from the randomization to progression or relapse per investigator assessment per the Lugano classification criteria, or death.

    Time frame: Neither participant was a responder, therefore DOR was not followed. EFS and PFS were followed from first dose of study treatment until disease progression, subsequent anticancer therapy, or death. EFS and PFS were followed for 0.99 to 1.84 months.

  6. Overall Response Rate of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review

    To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Overall Response Rate (ORR), and assessed by investigator assessments between treatment arms. ORR in FCA vs FC alone per investigator assessment at any time up through commencement of new anti-cancer therapy or withdrawal of consent.

    Time frame: Overall Response Rate was followed until disease progression or subsequent anticancer therapy, whichever occurred earlier. Specifically, ORR was followed for 0.99 to 1.84 months for each participant in the FCA and FC arm, respectively.

  7. Depth and Duration of a Lymphodepletion Regimen Containing FCA vs FC

    To characterize the depth and duration of lymphodepletion with and without ALLO-647, as assessed by lymphocyte count.

    Time frame: From study treatment to study discontinuation, death, withdrawal of consent, or date of initiation of another anticancer therapy, whichever occurs first, for a maximum of 9 months. Only Day 28 lymphocyte counts are available for both participants.

  8. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    To evaluate the overall safety profile of ALLO-647 by comparing FCA lymphodepletion with FC lymphodepletion.

    Time frame: Up to 60 months, study completion, or death, whichever occurs earlier. TEAEs were followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.

  9. Incidence of ALLO-501A Related Treatment Emergent Adverse Events

    To evaluate the overall safety profile of ALLO-501A following lymphodepletion.

    Time frame: Up to 60 months, study completion, or death, whichever occurs earlier. Related TEAEs were followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.

08

Results

Posted Dec 31, 2025
Limitations and caveats
ALLO-647-201 (EXPAND) was a Phase 2 study that was terminated prior to completion for reasons not related to safety or efficacy concerns. No analyses of the baseline, disposition, safety, primary, secondary, nor exploratory endpoints were performed due to the limited enrollment and data collected during the study. Data were listed but not summarized.

Participant flow

The study enrolled participants from the United States and Europe. The informed consent date of the first participant was 01 November 2023, and the informed consent date of the last participant was 04 December 2023. The study was terminated prior to completion for business reasons, not due to safety or efficacy concerns.

Participant flow — Overall Study
MilestoneLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Started11
Completed00
Not completed11
Withdrew: Death11

Outcome measures

PrimaryProgression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review Committee

To assess the clinical efficacy of ALLO-647 (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by PFS and assessed by Independent Review Committee (IRC) in subjects with R/R (Relapsed / Refractory) LBCL (Large B Cell Lymphoma). In this study, PFS is defined as the time from randomization to disease progression, or relapse per the Lugano classification criteria (Cheson et al, 2014) as assessed by IRC or death.

Time frame:
Up to 60 months
Reported as:
Median · Participants

No measurements were reported for this outcome.

SecondaryOverall-response Rate (ORR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee

To assess the clinical efficacy of ALLO-647 as measured by ORR and assessed by Independent Review Committee (IRC) between treatment arms. ORR is defined as best overall response (Complete Response and Partial Response, assessed using the Lugano classification criteria 2014; Cheson , et al, 2014) by IRC at any time up through commencement of new anti-cancer therapy or withdrawal of consent.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Overall-response Rate (ORR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee
ParticipantsLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Overall-response Rate (ORR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee00
SecondaryEvent-Free-Survival (EFS) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee

To assess clinical efficacy of ALLO-647 with FC (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by Event-Free Survival (EFS) and assessed by Independent Review Committee (IRC) in subjects with R/R LBCL. EFS is defined as the time from randomization to disease progression or relapse per the Lugano classification criteria 2014 as assessed by IRC, new anti-cancer therapy, or death.

Time frame:
Up to 60 months
Reported as:
Median · Participants

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee

To characterize the efficacy of ALLO-647 as measured by Duration of Response (DOR) and assessed by Independent Review Committee (IRC) between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse (per IRC) or death.

Time frame:
Up to 60 months
Reported as:
Median · Participants

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) of a Lymphodepletion Regimen Containing FCA vs FC

To characterize the efficacy of ALLO-647 as measured by OS, defined as the time from randomization to death.

Time frame:
Up to 60 months, study completion, or death, whichever occurs earlier. Specifically, OS was followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.
Reported as:
Median · Months
Overall Survival (OS) of a Lymphodepletion Regimen Containing FCA vs FC
MonthsLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Overall Survival (OS) of a Lymphodepletion Regimen Containing FCA vs FC4.50 (4.50 to 4.50)10.09 (10.09 to 10.09)
SecondaryDuration of Response, Event-Free Survival and Progression-Free Survival of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review

To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Duration of Response (DOR), Event-Free Survival (EFS), Progression-Free Survival (PFS), assessed by investigator assessments between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse per investigator assessment, or death. EFS is defined as the time from randomization to disease progression or relapse per investigator assessment per the Lugano classification criteria, new anti-cancer therapy, or death. PFS is defined as time from the randomization to progression or relapse per investigator assessment per the Lugano classification criteria, or death.

Time frame:
Neither participant was a responder, therefore DOR was not followed. EFS and PFS were followed from first dose of study treatment until disease progression, subsequent anticancer therapy, or death. EFS and PFS were followed for 0.99 to 1.84 months.
Reported as:
Median · Months
Duration of Response, Event-Free Survival and Progression-Free Survival of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review
MonthsLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Progression-Free Survival0.99 (0.99 to 0.99)1.84 (1.84 to 1.84)
Event-Free Survival0.99 (0.99 to 0.99)1.84 (1.84 to 1.84)
SecondaryOverall Response Rate of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review

To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Overall Response Rate (ORR), and assessed by investigator assessments between treatment arms. ORR in FCA vs FC alone per investigator assessment at any time up through commencement of new anti-cancer therapy or withdrawal of consent.

Time frame:
Overall Response Rate was followed until disease progression or subsequent anticancer therapy, whichever occurred earlier. Specifically, ORR was followed for 0.99 to 1.84 months for each participant in the FCA and FC arm, respectively.
Reported as:
Count of participants · Participants
Overall Response Rate of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review
ParticipantsLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Overall Response Rate of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review00
SecondaryDepth and Duration of a Lymphodepletion Regimen Containing FCA vs FC

To characterize the depth and duration of lymphodepletion with and without ALLO-647, as assessed by lymphocyte count.

Time frame:
From study treatment to study discontinuation, death, withdrawal of consent, or date of initiation of another anticancer therapy, whichever occurs first, for a maximum of 9 months. Only Day 28 lymphocyte counts are available for both participants.
Reported as:
Mean · cells/cubic millimeter
Depth and Duration of a Lymphodepletion Regimen Containing FCA vs FC
cells/cubic millimeterLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Depth and Duration of a Lymphodepletion Regimen Containing FCA vs FC300 (300 to 300)417 (417 to 417)
SecondaryIncidence of Treatment-Emergent Adverse Events (TEAEs)

To evaluate the overall safety profile of ALLO-647 by comparing FCA lymphodepletion with FC lymphodepletion.

Time frame:
Up to 60 months, study completion, or death, whichever occurs earlier. TEAEs were followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Adverse Events (TEAEs)
ParticipantsLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Incidence of Treatment-Emergent Adverse Events (TEAEs)11
SecondaryIncidence of ALLO-501A Related Treatment Emergent Adverse Events

To evaluate the overall safety profile of ALLO-501A following lymphodepletion.

Time frame:
Up to 60 months, study completion, or death, whichever occurs earlier. Related TEAEs were followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.
Reported as:
Count of participants · Participants
Incidence of ALLO-501A Related Treatment Emergent Adverse Events
ParticipantsLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Incidence of ALLO-501A Related Treatment Emergent Adverse Events10

Adverse events

Collected over From participant's first dose date of any study drug up to 60 months post ALLO-647 infusion, date of death, date of study discontinuation, or the date of initiation of another anti-cancer agent, whichever occurs first; follow up of the participants ended within 11 months after ALLO-501A infusion due to death as a result of disease progression.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)1/1 (100%)0/1 (0%)1/1 (100%)
Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)1/1 (100%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventLymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)
Sinus TachycardiaCardiac disorders1/10/1
FatigueGeneral disorders1/10/1
FallInjury, poisoning and procedural complications1/10/1
Electrocardiogram QT prolongedInvestigations1/10/1
HyponatremiaMetabolism and nutrition disorders1/10/1
HypokalemiaMetabolism and nutrition disorders1/10/1
HypophosphataemiaMetabolism and nutrition disorders1/10/1
Tumor lysis syndromeMetabolism and nutrition disorders1/10/1
DysgeusiaNervous system disorders1/10/1
Pleural effusionRespiratory, thoracic and mediastinal disorders1/10/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)Total
<=18 years000
Between 18 and 65 years112
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)Total
FemaleNANANA
MaleNANANA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)Total
American Indian or Alaska NativeNANANA
AsianNANANA
Native Hawaiian or Other Pacific IslanderNANANA
Black or African AmericanNANANA
WhiteNANANA
More than one raceNANANA
Unknown or Not ReportedNANANA
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)Total
Hispanic or LatinoNANANA
Not Hispanic or LatinoNANANA
Unknown or Not ReportedNANANA
Region of Enrollment
Region of Enrollment(Participants)Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA)Lymphodepletion With Fludarabine, and Cyclophosphamide (FC)Total
United States101
Belgium011
09

Study locations

2 sites
  • University of Louisville James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2024, 3 months.

Results were first posted in Dec 2025, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Feb 6, 2023
StartActual
Nov 1, 2023
Primary completionActual
Feb 20, 2024
CompletionActual
Oct 28, 2024
Results first posted
Dec 31, 2025
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05714345
Lead sponsor
Allogene Therapeutics
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Nov 1, 2023
Primary completion
Feb 20, 2024
Completion
Oct 28, 2024
Results posted
Dec 31, 2025
Last update
Mar 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cyclophosphamide

Start the discussion